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eDITORIAL COMMENT
ostoperative Atrial
ibrillation and Mortality:
o the Risks Merit
hanges in Clinical Practice?*
aniel Levy, MD, FACC,†‡§
illiam B. Kannel, MD, FACC†
ethesda, Maryland; Framingham and
oston, Massachusetts
trial fibrillation (AF), the most common sustained cardiac
hythm disturbance, is estimated to afflict more than 2
illion people in the U.S. (1). The incidence of AF is highly
ge dependent, roughly doubling with each successive de-
ade of age in both men and women from 3 and 2 cases,
espectively, per 1,000 person-years from ages 55 to 64 years
o 38 and 31 cases per 1,000 person-years from ages 85 to 94
2). The prevalence of AF has increased in recent years;
rom 1968 to 1989, the prevalence of AF in Framingham
eart Study subjects 65 to 84 years of age rose from 3.2%
n men and 2.8% in women to 9.1% and 4.7%, respectively
3). During the last two decades of the 20th century, the
See page 742
umber of hospital discharges with a diagnosis of AF
ncreased more than twofold (4). In addition, a recent
ational Center for Health Statistics death certificate re-
iew revealed an increase in deaths with a diagnosis of AF;
rom 1980 to 1998, the number of decedents with AF
ripled (5). It is likely that with the aging of the U.S.
opulation and advances in awareness of the consequences
f AF and the widespread use of improved methods of
rrhythmia detection, the number of people with a diagnosis
f AF will continue to grow (6). In light of these trends, AF
as been referred to as an emerging epidemic (7).
Although AF was recognized long ago as a hazard for
troke in patients with rheumatic heart disease, the magni-
ude of the cardiovascular risk of nonrheumatic AF in the
eneral population was not appreciated until results from
pidemiological investigations were reported in the 1980s
8,9). Atrial Fibrillation is now widely recognized as a risk
actor for stroke and other thromboembolic complications
nd for heart failure (HF), leading to a substantial disease
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †National Heart, Lung, and Blood Institute’s Framingham Heart Study,
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oston University School of Medicine, Boston, Massachusetts. The Framinghamveart Study is supported by NHLBI contract N01-HC-25195.urden and medical costs (1). In addition, AF is associated
ith increased mortality. In the Framingham Heart Study,
F was associated with a 1.5-fold increase in risk for death
rom all causes in men and 1.9-fold increase in women (10).
Whereas the hazards due to chronic AF are well estab-
ished, the prognostic implications of AF after cardiac
urgery are less certain. AF is common after heart surgery,
specially in the elderly. Its reported postoperative incidence
n recent studies varies from about 20% to 50% (6). Until
ecently, the prevailing opinion was that postoperative AF is
ransient and that its prognosis is mostly benign. That
pinion, however, is changing. In a series of nearly 4,000
atients undergoing cardiac surgery, Creswell et al. (11)
eported a 31.9% incidence of atrial arrhythmias, the most
ommon being AF. In that series, postoperative AF was
ssociated with increased risk for stroke, prolonged length
f hospital stay, and the occurrence of ventricular tachycar-
ia or fibrillation.
In this issue of the Journal, Villareal et al. (12) at the
exas Heart Institute report an association of postoperative
F with increased risk for short-term and long-term ad-
erse outcomes in patients undergoing coronary bypass
urgery. In this large case series, drawn from 6,477 patients
ndergoing a first coronary bypass, the incidence of post-
perative AF was 16%. Patients with postoperative AF were
icker than those who did not develop this arrhythmia; risk
actors for its occurrence included advanced age, hyperten-
ion, congestive HF, a history of previous peripheral vascu-
ar or cerebrovascular disease, chronic obstructive lung
isease, more diseased coronary arteries, obesity, and the
eed for an intra-aortic balloon pump. In the short term,
atients with AF were at increased risk for stroke and death,
nd they also had longer and more complicated hospital
tays. In the long term, patients with AF were at increased
isk for death (relative risk 1.5; 95% confidence interval 1.3
o 1.8). Other predictors of increased mortality risk were
dvance age, congestive HF, history of previous peripheral
ascular or cerebrovascular disease, diabetes, renal insuffi-
iency, the number of diseased coronary arteries, and the use
f an intra-aortic balloon pump. Thus, many of the risk
actors that predicted the occurrence of postoperative AF
lso predicted long-term mortality (12). These intertwined
hreads illustrate the complexity in distinguishing the in-
rinsic hazards due to postoperative AF from the risks
elated to its etiologic factors, and they underscore the
nherent challenge of establishing an independent contribu-
ion of AF to mortality.
In assessing the prognostic importance of transient AF in
he postoperative setting, an independent relation is credible
f mechanisms for a direct adverse effect can be postulated.
lausible mechanisms for direct harm due to AF are HF
nd recurrent AF with attendant thromboembolic sequelae.
he links between AF and HF are well established. Animal
xperiments and case reports indicate that AF with rapid
entricular response can predispose to dilated cardiomyop-
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Editorial Comment March 3, 2004:749–51thy within weeks and that loss of atrial function may
recipitate HF by eliminating the atrial systolic contribution
o left ventricular filling and thereby reducing cardiac output
13). The resulting neurohormonal activation can perpetu-
te a vicious cycle and make both the AF and HF refractory
o treatment (14). Atrial fibrillation and HF have a tendency
o occur together, either because of shared underlying risk
actors or because one can directly lead to the other. Data
rom the Framingham Heart Study indicate that HF is a
otent risk factor for AF; it antedated or accompanied the
evelopment of AF in 26% of cases (15) and it imposed a
ix- to eight-fold risk of developing the arrhythmia (2).
trial fibrillation also predisposes to the development of
F; a quarter of Framingham Heart Study subjects with
F had a history of previous or concurrent AF (15). Not
nly will a large proportion of persons with AF or HF
evelop the other condition, but the concurrence of AF and
F is associated with a poor prognosis (15).
Although the study by Villareal et al. (12) nicely summa-
izes a large clinical experience with postoperative AF, many
uestions remain unanswered. Most pressing, we must
onsider three explanations for the reported association of
F with mortality and whether it is: 1) directly due to AF
nd its inherent complications, 2) a consequence of treat-
ent of AF, or 3) a reflection of residual confounding. Let
s consider each of these three possible explanations.
IRECT IMPACT
irst, the Villareal (12) investigation does not report cause
f death in patients with postoperative AF and as such does
ot provide insight into a plausible direct mechanism
inking AF with mortality. If we knew, for example, that the
xcess mortality was largely due to an increase in risk for
mbolic stroke, we could infer causation and consider
ong-term anticoagulation as a possible means by which
ortality in patients with postoperative AF can be reduced.
nfortunately, the absence of data—even from death cer-
ificates—on cause of death precludes such speculation.
REATMENT EFFECT
econd, it is possible to speculate that increased mortality in
ostoperative AF is a consequence of treatment. For exam-
le, antiarrhythmic drugs, which were prescribed at dis-
harge to nearly one third of patients with postoperative AF
12), can have untoward and potentially lethal proarrhyth-
ic properties (16). Although Villareal et al. (12) demon-
trated that among patients with postoperative AF the use
f antiarrhythmic treatment was associated with lower
ortality, this was derived from a subgroup analysis and not
n analysis of the entire study sample. It is also possible that
atients with postoperative AF are undertreated with regard
o their risk for embolic events. The proportion of AF
atients discharged on aspirin was not reported, and only
4% of patients with postoperative AF were discharged on
nticoagulation; whether or not higher rates of antiplatelet cherapy or anticoagulation could have reduced mortality in
atients with postoperative AF cannot be determined.
ESIDUAL CONFOUNDING
hird, we must consider residual confounding as an expla-
ation for the reported 50% higher mortality risk associated
ith postoperative AF. In the multivariable analyses, nu-
erous risk factors were adjusted for, but the adequacy of
he adjustment was limited to the variables entered into the
odel. Some key determinants of both AF risk and out-
ome were not entered in the multivariable model. Two
xamples are the failure to adjust for AF status upon
ischarge or for the presence and severity of valvular heart
isease. Inadequate adjustment for risk factors also may
ave contributed to residual confounding. Specifically, in
he multivariable analyses, age was entered as 65 years
ersus younger, yet the relationship of age to risk of AF and
o mortality is so powerful that the categorical variable used
o capture its effect may be insufficient. In addition, as in any
ohort study, the analyses can only adjust for measured
ovariates and not for risk factors that were not measured. In
n attempt to address the problem of incomplete accounting
or covariates, the authors conducted a subgroup analysis in
hich AF cases and controls were matched on as many
ariables as possible. Unfortunately, fewer than 20% of AF
ases are represented in this matched-set analysis. The AF
ubgroup selected for this analysis was not representative of
he far-larger AF sample from which it was drawn. The 195
F patients in the matched analysis differed from the overall
F sample with regard to multiple traits including age (66
s. 68 years), gender (18% vs. 27% women), and prevalence
f previous myocardial infarction (9% vs. 17%), cerebrovas-
ular disease (1% vs. 8%), peripheral vascular disease (12%
s. 28%), and diabetes (3% vs. 11%). Despite attempts to
ccount for confounding, it remains distinctly possible that
F was associated with mortality because it occurs in sicker
atients and the contention that postoperative AF is an
ndependent predictor of mortality is incompletely substan-
iated.
Is the finding of increased mortality in patients with AF
ufficient evidence to change current clinical practice? For
xample, are the results of this study so compelling that we
hould recommend perioperative antiarrhythmic therapy as
means to prevent postoperative AF and thereby reduce
ortality? Or, does this report provide sufficient indication
f mechanism of harm that, even if postoperative AF is
ransient, prolonged anticoagulation is necessary? In con-
idering the answer to these questions, we must be cogni-
ant of the fact that observational data can establish an
ssociation between a risk factor and an outcome and
etermine the magnitude of the associated risk, but they
annot establish causation. In the absence of evidence to
upport a causal pathway linking AF with mortality, there
re insufficient grounds to recommend changes in current
linical practice guidelines. In light of the considerable risk
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March 3, 2004:749–51 Editorial Commentor morbidity and mortality associated with postoperative
F, widespread adoption of proven prevention strategies is
arranted, including prophylactic treatment with beta-
locking agents, unless contraindicated (6). In addition,
nticoagulation for patients with persistent or recurrent
ostoperative AF, as in patients with nonsurgical AF, is
ndicated. A recent large clinical trial in patients with
onsurgical AF suggested superiority of a strategy of rate
ontrol plus anticoagulation to one of rhythm control (17).
ompared with rhythm control, the rate control plus
nticoagulation strategy resulted in lower mortality in older
atients and those with coronary disease. Whether or not
he benefits of rate control and anticoagulation extend to
oronary artery bypass patients with postoperative AF re-
ains to be determined.
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